Company intelligence / Profile preview

Sensorion

Ownership: Public · ALSEN
Employees: ~63
Development stage: Phase 2

Overview

Sensorion’s lead small molecule candidate SENS‑401 has completed a Phase 2a proof-of-concept study showing positive results in preserving residual hearing post-cochlear implantation. The same molecule is in ongoing Phase 2 studies for cisplatin-induced ototoxicity with topline data expected by late H2/2025. Their lead gene therapy candidate SENS‑501 targeting otoferlin deficiency initiated a Phase1/2 trial ("Audiogene") in early 2024, with safety as primary endpoint for dose escalation cohorts. The company also received EMA agreement on Pediatric Investigation Plan for this program[1][2][4].

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Small molecules (e.g., SENS-401/Arazasetron)Gene therapy (AAV-based dual vector gene therapies like SENS-501 and GJB2-GT)
Industry: Biotech

Drug pipeline

4 assets

arazasetron besylate

3 more assets in the full pipeline.

Request access →

Partnerships

Strategic collaboration with Institut Pasteur focusing on genetics of hereditary deafness including development of their two main gene therapy candidates[1][4]Partnership with Cochlear Limited for clinical study involving cochlear implant patients treated with SENS‑401[1]

Beyond the preview

Go deeper on Sensorion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensorion.

Explore the full profile